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Introduction
miRNAs are small endogenous non–protein-coding RNAs that 
posttranscriptionally regulate the expression of multiple target 
genes in different cell types. In this manner, miRNAs control many 
physiological cellular processes, as well as several pathologies. 
Widespread dysregulation of miRNA expression has been report-
ed in tumor cells, with either an oncogenic or a tumor suppressive 
role (1). Given their pivotal role in tumor initiation, progression, 
and response to therapy, these molecules have been accepted as 
potential cancer biomarkers (2). During neoplastic development, 
miRNAs have also been reported to be dysregulated in cells from 
the tumor microenvironment (TME) (3). Therefore, their role in 
cancer progression is not just limited to regulating cancer cell 
behavior. The nonmalignant cells of the TME have a dynamic 
and often tumor-supporting function (4), thus contributing to 
the clinicopathological profile and to the efficacy of anticancer 
therapy. The TME contains diverse types of cells, including cells 
of the immune system, endothelial cells, and fibroblasts. Recent 
studies have begun to unravel the cell-autonomous significance of 
miRNAs in macrophages, T cells, and endothelial cells (ECs) and 
their potential implications for cancer (5–7).
miR-21 is the most commonly upregulated miRNA in solid 
tumors and hematological malignancies, and many studies have 
linked this cancer-associated microRNA (oncomiR) to poor prog-
nosis and survival (8). The contribution of miR-21 to tumorigene-
sis has been extensively studied in the context of cancer cells, as 
it regulates various downstream effectors associated with tumor 
pathogenesis including cell invasion, proliferation, migration, 
apoptosis, and chemoresistance (8, 9). The role of miR-21 in cells 
of the TME, however, has not been comprehensively studied. miR-
21 is the most abundant miRNA in macrophages (10) and highly 
expressed in ECs and T lymphocytes (11, 12). Several reports have 
described the role of miR-21 in regulating cellular functions that 
may have an impact on tumor growth, such as the inflammato-
ry responses of macrophages, T-cell activation and endothelial 
angiogenic functions (12–18). However, the conclusions of these 
reports are inconsistent and in most cases are not directly studied 
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exhibited an increased number of TUNEL-positive cells (Figure 
1C) and reduced tumor-associated vasculature, as shown by the 
diminished CD31+ vessel-like structures (Figure 1D). These results 
indicate that loss of miR-21 increases tumor cell death, diminishes 
tumor angiogenesis, and provides evidence that miR-21 expres-
sion in cells other than cancer cells has an important role in pro-
moting tumor growth.
Lack of miR-21 expression in immune cells is responsible for 
reduced tumor burden. To eliminate the role of stromal cells (e.g., 
fibroblasts, ECs) in limiting tumor growth of miR-21–/– mice, WT 
mice were lethally irradiated and subsequently transplanted with 
WT or miR-21–/– BM. Mice transplanted with miR-21–/– BM devel-
oped smaller tumors (Figure 2, A and B). Histological analysis of 
their tumors revealed both increased TUNEL-positive cells and 
decreased vascularization (Figure 2, C and D). Interestingly, a 
reverse transplant of WT or miR-21–/– BM into miR-21–/– mice result-
ed in larger tumors in mice transplanted with WT BM (Figure 2, E 
and F), with decreased TUNEL-positive cells and increased CD31+ 
vessel- like structures (Figure 2, G and H). These results suggest 
that miR-21 expression within the tumor immune infiltrate is 
responsible for promoting tumor growth and that its deletion caus-
es increased tumor cell death and decreased tumor angiogenesis.
Tumor immune infiltrate of miR-21–/– or WT mice adoptively 
transferred with miR-21–/– BM is characterized by the presence of 
tumor-associated macrophages with an enhanced differentiated phe-
notype. Then, we examined the tumor-infiltrating immune cells 
in LLC tumors of either WT or miR-21–/– mice as well as WT mice 
adoptively transferred with WT or miR-21–/– BM. We analyzed the 
frequency of immune cells related to tumor development, includ-
ing myeloid-derived suppressor cells (MDSCs), tumor-infiltrating 
lymphocytes (TILs), and macrophages (4). We did not find differ-
in the context of tumor progression. In other instances, the stud-
ies relied on culture systems to inhibit or overexpress miR-21, or 
approaches to globally target miR-21 in a non–cell/tissue-specific 
manner (19–23). Recent attempts to understand the role of miR-
21 within immune infiltrating cells have also yielded conflicting 
results mostly due to lack of experimental data on cell-type specif-
ic KO or cell-type specific targeting approaches (24, 25).
In this work, we have analyzed the function of miR-21 in non-
cancerous cells of the TME to determine its contribution to tumor 
progression. To this end, we used a syngeneic tumor mouse model 
and comprehensively assessed the effect of miR-21 deficiency in 
different cells/tissues on tumor progression. Briefly, our results 
indicate that the expression of miR-21 in macrophages of the tumor 
immune infiltrate plays a pivotal role in the regulation of tumor 
progression. Specifically, we found that both deletion and targeted 
inhibition of miR-21 in tumor-associated macrophages promotes 
proinflammatory angiostatic functions. This results in reduced 
tumor neovascularization and an antitumoral immune response, 
which is characterized by a macrophage-mediated improvement 
of cytotoxic T-cell responses. Together, these effects led to dimin-
ished tumor growth.
Results
miR-21–deficient mice develop smaller tumors. In this study, we 
aimed to analyze the role of miR-21 in noncancerous cells of the 
TME on regulation of tumor progression. We used the Lewis lung 
carcinoma (LLC) model, which is a syngeneic, hence immunolog-
ically compatible model, and analyzed tumor growth in both WT 
and miR-21 KO mice (miR-21–/–). As shown in Figure 1, A and B, 
miR-21–/– mice developed tumors with reduced volume and weight 
when compared with WT controls. Tumors of miR-21–/– mice 
Figure 1. miR-21–deficient mice develop smaller tumors. 
(A–D) Tumor analysis of WT and miR-21–/– mice with s.c. 
injection of LLCs in the dorsal flank (n = 5). Tumor volume (A), 
final tumor weight (B). (C) Representative images of TUNEL 
and DAPI staining of cross sections of LLC tumors. Right panel: 
Quantification of %DAPI+ TUNEL+ cells. (D) Representative 
images of CD31 and DAPI immunostaining. Right panel: Quan-
tification of CD31+ vessel-like structures. Results are mean ± 
SEM. *P < 0.05. (A) Two-way ANOVA (time and genotype) with 
Bonferroni correction, #P < 0.05 individual comparisons. (B–D) 
Mann-Whitney U test. (A–D) Representative experiments out 
of 3 with similar results. Scale bars: 70 μm.
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BM (Supplemental Figure 1, B and C). Furthermore, the 
proportion of IFNG expressing CD4+ or CD8+ T cells 
was similar in tumors from WT and miR-21–/– mice (Sup-
plemental Figure 1D), suggesting that the percentage of 
activated T cells was equivalent.
We did, however, find a significant reduction in 
TAM infiltration in miR-21–/– mice and mice transferred 
with miR-21–/– BM (Figure 3, A and B) and a decreased 
percentage of TAMs expressing C-C chemokine recep-
tor type 2, although the level of surface expression was 
not affected (Supplemental Figure 1E). In both miR-21–/– 
animals and mice transferred with miR-21–/– BM, we 
found that infiltrated TAMs exhibited increased surface 
expression of MHC class II (MHC II) (Figure 3, C and 
D). MHC II+high TAMs are better fosters of antitumor 
immune responses (26). Altogether, these data show 
that macrophages lacking miR-21 have reduced infiltra-
tion into the TME, and those present have a phenotype 
more associated with tumor growth suppression.
Expression of miR-21 in TAMs regulates disease out-
come. miR-21 is the most consistently overexpressed 
miRNA across tumor types (8) and is associated with 
poor prognosis (27). In solid tumors, these analyses 
were based on total tumor RNA, which lacks critical 
spatial information. We used quantitative ISH (qISH) to 
directly assess the colocalization of miRNA expression 
with tumor epithelial and/or other subcellular com-
partments by multiplexing with DAPI and cytokeratin 
immunofluorescence (28, 29). To determine the prog-
nostic value of miR-21 expression in the major tumor 
compartments tumor islets [TIs] vs. TME), we used 3 
retrospective non–small cell lung carcinoma (NSCLC) cohorts from 
Yale University (Supplemental Tables 1–3). NSCLC represents the 
most common subtype of lung cancer (30). These tissue microar-
rays (TMA) termed YTMA 79, 14, or 250, are composed of surgi-
cal resection samples from 290 patients with NSCLC. In order to 
validate miR-21 qISH, we first assessed miR-21 qISH on heart and 
ences in the percentage of MDSCs in the tumors of miR-21–/– mice 
or the proportion of monocytic or granulocytic MDSCs (Supple-
mental Figure 1A; supplemental material available online with 
this article; https://doi.org/10.1172/JCI127125DS1). We also did 
not detect differences in the percentage of CD4+ or CD8+ T cells in 
tumors from miR-21–/– mice or tumors from WT mice with miR-21–/– 
Figure 2. Hematopoietic miR-21 regulates and promotes 
tumor progression. (A–D) Tumor analysis of WT mice 
transplanted with WT or miR-21–/– BM and injected with LLCs 
s.c. (n = 7). LLC tumor volume (A), final tumor weight (B). (C) 
Representative images of TUNEL and DAPI staining of cross 
sections of LLC tumors. Right panel: Quantification of %DAPI+ 
TUNEL+ cells (n = 5 out of 7 randomly selected). (D) Represen-
tative images of CD31 and DAPI immunostaining. Right panel: 
Quantification of CD31+ vessel-like structures (n = 6 out of 7 
randomly selected). (E–H) Tumor analysis of miR-21–/– mice 
transplanted with WT or miR-21–/– BM cells and injected with 
LLCs s.c. (n = 5). Tumor volume (E), final tumor weight (F). (G) 
Representative images of TUNEL and DAPI staining of cross 
sections of LLC tumors. Right panel: Quantification of %DAPI+ 
TUNEL+ cells. (H) Representative images of CD31 and DAPI 
immunostaining. Right panel: Quantification of CD31+ vessel- 
like structures (n = 4 out of 5 randomly selected). Results are 
mean ± SEM. *P < 0.05. (A and E) Two-way ANOVA (time and 
genotype) with Bonferroni correction, #P < 0.05 individual 
comparisons. (B–D and F–H) Mann-Whitney U test. (A–H) 
Representative experiments out of 2 with similar results. 
Scale bars: 70 μm.
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with colorectal cancer (33). In patients with lung cancer, conflict-
ing data have been reported (34, 35). We used CD68 immunoflu-
orescence to detect macrophages in our TMAs and found CD68+ 
macrophages present in all tumor TMA spots of NSCLC cohorts (n 
= 240) in both the TI and TME (Figure 4D). A total of 50.1% of all 
miR-21–expressing cells were CD68+ (Figure 4F). Although TME 
areas were slightly enriched in CD68+ miR-21+ cells (Figure 4G), 
double positive cells could be found in both compartments (Figure 
4E), and the level of miR-21 expression was similar (Figure 4E). 
We thus analyzed the contribution of miR-21 expression in macro-
phages to patients’ survival. We found that the level of expression 
of miR-21 in CD68+ cells present within TI was not associated with 
5-year OS (Figure 4H). When the analysis was performed within 
the TME (Figure 4I), however, there was significantly worse sur-
vival for patients with high levels of miR-21 in CD68+ cells when 
they were stratified by the median. Combined analysis of the 
expression of miR-21 in CD68+ cells of TI and the TME (Figure 
4J) showed a slight reduction in patients’ survival when miR-21 is 
high in tumor macrophages. Altogether, these data indicate that 
although miR-21 expression in macrophages is heterogeneously 
localized within the tumor, the level of expression of miR-21 in 
macrophages and in particular, in macrophages within the TME 
can predict patient survival.
miR-21–deficient TAMs express a gene signature associated with 
the promotion of a robust antitumor immune function. To elucidate 
the role of miR-21 in regulating TAM function, we isolated TAMs 
from LLC tumors of either miR-21–/– or WT mice and profiled their 
transcriptomes by RNA-Seq. miR-21–/– TAM gene expression pat-
terns were distinct from WT TAMs (Supplemental Figure 3A). 
Hierarchical clustering of log ratio transformed gene expression 
values of 1,035 genes that were differentially and significantly 
expressed (FC > 1.5, P ≤ 0.005 B-H FDR) showed the level of tran-
spleen tissue from an miR-21–/– mouse (28). No specific signal for 
miR-21 could be detected in heart and spleen compared with nor-
mal WT (Supplemental Figure 2A). On the TMA, we found that the 
expression of miR-21 in tumor epithelial cells within TI was not 
associated with 5-year overall survival (OS) (Figure 4A). In non- 
tumor cells of the TME (Figure 4B), however, there was significant 
prognostic effect on 5-year OS with a worse survival for patients 
with high levels of miR-21 expression if they were stratified by the 
median. Combined analysis of the expression of miR-21 in TI and 
the TME did not show a significant effect on OS (Figure 4C). This 
finding indicates that high miR-21 expression in cells of the TME 
(non-tumor cells) has a negative impact on OS.
We then analyzed the expression of miR-21 in both compart-
ments and found that the level of miR-21 expression was slightly 
higher in TI when compared with the TME (Figure 4D). Despite 
this fact, high expression of miR-21 in the TME was associated with 
a worse prognostic value (Figure 4B). This finding is in agreement 
with data showing that miR-21 expression in noncancerous cells of 
the tumor contributes to the pathogenesis of lung cancer (31).
miR-21 is highly expressed in the monocytic/macrophage lin-
eage (32) and the most abundant miRNA in macrophages (10). In 
order to determine the levels of miR-21 in immune cells of LLC 
tumors, we challenged WT mice with eGFP-LLCs and after 14 
days, TAMs (CD45+, CD11b+, MHC II+, F4/80+), LLCs (eGFP+) and 
TILs (CD45+, F4/80–) were sorted and the miR-21 levels analyzed. 
Within the tumor, we found that miR-21 was highly expressed in 
TAMs compared with the rest of the immune infiltrate and tumor 
cells (eGFP-LLCs) (Supplemental Figure 2B). Likewise, miR-21 
levels were higher in BM-derived macrophages (BMDMs) com-
pared with LLCs in culture (Supplemental Figure 2C).
A high density of TAMs was associated with worse survival in 
gastric cancer and head and neck cancer but better OS in patients 
Figure 3. TAMs of miR-21–/– or WT mice adoptively transferred with miR-21–/– BM have an enhanced differentiated phenotype. (A) Left panel: Represen-
tative flow cytometry plots of TAM detection in s.c. LLC tumors of WT and miR-21–/– mice. TAMs were gated as CD45+ CD11b+ MHC II+ F4/80+ cells of the 
digested tumor. Right panel: Average % TAMs (n = 4 out of 5 randomly selected). (B) Average % TAMs of LLC tumors in WT mice transplanted with WT or 
miR-21–/– BM cells (n = 6 out of 7 randomly selected). (C and D) Representative histograms of MHC II surface expression in TAMs of s.c. LLC tumors of WT 
or miR-21–/– (C), or WT mice transplanted with WT or miR-21–/– BM cells (D) a.u.f., arbitrary units of fluorescence. Right panels: Average MFI (n = 4 out of 5 
randomly selected for C or n = 6 out of 7 randomly selected for D). Results are mean ± SEM. (A–D) *P < 0.05, Mann-Whitney U test. (A and D) Representa-
tive experiments out of 3 with similar results. (B and D) Representative experiments out of 2 with similar results.
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nication between innate and adaptive immune cells, Th1 pathway, 
and a proinflammatory gene profile (Figure 5B). Conversely, a 
metabolic gene pattern, that in macrophages is linked to anti- 
inflammatory functions, and a Th2 gene signature were dimin-
ished in miR-21–/– TAMs (Figure 5B). Similarly, the top overrepre-
scriptional dysregulation between each genotype and highlighted 
the similar expression patterning found among biological repli-
cates in each group (Figure 5A). Ingenuity pathway analysis (IPA) 
of both up- and downregulated genes (Figure 5B) in miR-21–/– TAMs 
identified gene signatures that favor cytokine-mediated commu-
Figure 4. High expression of miR-21 in CD68+ cells of the TME of NSCLC regulates disease outcome. (A–C) Kaplan-Meier 5-year OS survival curves of 
patients with NSCLC in a combined analysis of 3 Yale cohorts; patients were stratified by the median of normalized miR-21–positive cell counts in (A) TIs, 
(B) TME, and (C) total cells. (D) Quantitative immunofluorescence of miR-21 in TI and TME cell compartments. (E) Quantitative immunofluorescence inten-
sity of miR-21 in CD68+ cells in TI and TME cell compartments. (F) Analysis of the percentage of miR-21+ Cd68+ of total miR-21+ cells in the 3 Yale cohorts 
independently and combined. (G) Representative cytokeratin immunostaining, miR-21 FISH, and CD68 immunostaining of a random spot of YTMA250. 
Dashed lines delimit TI (cytokeratin-enriched areas) from TME. Arrowheads no. 1 and no. 2 indicate cytoketatin+ cells in TI with high or low miR-21 inten-
sity, respectively. Arrows no. 3 and no. 4 indicate CD68+ cells in TME with high or low miR-21 intensity, respectively. Arrows no. 5 and no. 6 indicate CD68+ 
cells in TI with high or low miR-21 intensity, respectively. Scale bar: 100 μm. (H–J) Kaplan-Meier OS survival curves of patients with NSCLC in a combined 
analysis of 3 Yale cohorts; patients were stratified by the top tertile of normalized double-positive cell counts (miR-21+ CD68+) in (H) TI, (I) TME, and (J) 
total cells. (A–C and H–J) Kaplan–Meier survival curves compared by log-rank test. *P < 0.05.
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sented disease and function categories pointed to an increased 
function of macrophages as antigen-presenting cells that promote 
activation of T lymphocytes (Figure 5C). Alternatively, gene sig-
natures related to tumor growth and the regulation of blood ves-
sel formation were downregulated (Figure 5C). Heatmaps with 
the list of regulated genes within these pathways and additional 
relevant functions are depicted in Figure 5, D–G and Supplemen-
tal Figure 3, B–D. Among the differentially expressed genes, Th1- 
Figure 5. Differential gene expression of TAMs in the absence of miR-21 expression. (A) Heatmap of hierarchical clustering log2-transformed gene 
expression values of the significantly differentially expressed genes (1,035) between miR-21–/– and WT TAMs (n = 4) isolated from s.c. LLC tumors. Colors 
displayed by row minimum and maximum values: yellow, higher expression; blue, lower). (B) IPA analysis of both up- (left) and down- (right) regulated 
genes in LLC TAMs lacking miR-21 expression vs. WT TAMs. (C) IPA of overrepresented disease or function categories upregulated (left) and downregulated 
(right) as a result of miR-21 deletion in TAMs of LLC tumors. (D–G) Heatmaps of significantly differentially expressed genes that contribute to (D) commu-
nication between innate and adaptive immune cells (E), Th1 pathway (F), IL-12 signaling in macrophages (G), and PPARa/RXRa activation.
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promoting and tumor- suppressive cytokines such as Il27 and Il12 
(36, 37) and the costimulatory molecules (38), Cd86 and Cd40, were 
upregulated in miR-21–/– TAMs (Supplemental Figure 3E). More-
over, we found increased expression of proinflammatory mediators 
including Tnf and Cxcl10 and Cxcl9 (Supplemental Figure 3E).
IL-12 is a reported target of mir-21 (15) and a strong inducer of 
Th1 responses, with demonstrated antitumor activity (37) that is 
produced by different immune cells including macrophages. The 
increased levels of Il12 found in miR-21–/– TAMs are consistent 
with lost miR-21–mediated targeting. To identify miR-21/mRNA 
associations relevant to TAM pathophysiology, we examined 
global correlation patterns between significantly upregulated 
genes in miR-21–/– TAMs and miR-21 predicted target genes (Fig-
ure 6A). We used a combination of 4 microRNA prediction algo-
rithms and selected genes that were predicted by at least 2 predic-
tion methods. Among the 321 significantly upregulated mRNAs, 
65 were predicted targets of miR-21 (Figure 6A). Together, they 
represented approximately 20% of the significantly upregulated 
genes found in miR-21–/– TAMs. These 65 significantly upregu-
lated and predicted targets of miR-21 were used as a data set for 
network analysis using the IPA Regulator Effects algorithm (Fig-
ure 6B). Downregulation of miR-21 was predicted as an upstream 
regulator, providing confidence of the predicted regulatory net-
work generated. Among the predicted upstream regulators, we 
found IL-21, IFNA, and IFNG, factors reported to have antitumor 
effects in a variety of murine experimental tumor models (39–41). 
The model also predicts IL-1B, a canonical proinflammatory cyto-
kine with antitumor roles (42), as an upstream regulator. The 
anticipated impact of the molecular expression changes showed 
an increase in downstream functions involved in inflammatory 
responses as well as the activation and homeostasis of leuko-
cytes. These data indicate that miR-21 depletion in TAMs causes 
a global rewiring of their transcriptional regulatory network that 
is skewed toward a proinflammatory phenotype and the promo-
tion of an antitumoral immune response (5, 42, 43). Proinflam-
matory stimulation of miR-21–/– BMDMs revealed a significant 
upregulation of proinflammatory gene signature, including Il12, 
Tnf, and Cxcl10 compared with WT BMDMs (Supplemental Fig-
ure 3F). These findings are in agreement with previous published 
data (10, 16) and support the idea that miR-21 deficiency primes 
macrophages to develop a proinflammatory program (43). In vivo, 
this translates to an antitumor phenotype when it happens in con-
junction with Th1 immune response (5, 42). Interestingly, a proin-
flammatory phenotype of TAMs in patients with NSCLC has been 
positively associated with survival time (44).
Increased IL12 in miR-21–deficient TAMs improves cytotoxicity 
of CD8+ T cells. Consistent with the TAM profiling data, we found 
that tumors from miR-21–/– mice had a higher percentage of IL-12+ 
and TNF+ TAMs (Figure 7, A and B, left panels) and also had higher 
levels of IL-12 and TNF (Figure 7, A and B, right panels). Similar 
results were observed in the tumors of WT mice transplanted with 
miR-21–/– BM (Figure 7, C and D). We also found increased levels 
of costimulatory molecules CD40 and CD86 (Figure 7E) linked to 
enhanced macrophage antitumor activity (38). These data, togeth-
er with the overall transcriptome signature exhibited by miR-21–/– 
TAMs, suggest that these cells could participate in enhancement 
of cytotoxic T-lymphocyte (CTL)–dependent cell death (45–47).
Increased intracellular levels of GZMB and higher levels of 
extracellular LAMP1 (CD107a) in tumor-infiltrated CD8+ T cells 
indicate better targeting and killing capacity of cancer cells by 
CTLs (48). We found that CD8+ T cells within the tumors of mice 
transplanted with miR-21–/– BM had higher levels of GZMB than 
their WT counterparts (Figure 7, F and G) and enhanced degranula-
tion status (Figure 7, H and I), as indicated by the larger number of 
CD8+ T cells with surface expression of CD107a (48). This finding 
is in agreement with the increased cell death observed in tumors 
of miR-21–/– or WT mice transplanted with miR-21–/– BM. However, 
the phenotype observed in CD8+ TILs could be mediated by the 
absence of miR-21 expression in these cells. Thus, we analyzed 
GZMB levels in CD8+ T cells isolated from the Peyer’s patches of 
healthy adult WT or miR-21–/– mice because in healthy and unchal-
lenged mice, CD8+ T cells from Peyer’s patches express high levels 
of GZMB (49). We did not find differences in GZMB levels (Sup-
plemental Figure 3G). Additionally, naïve splenic CD8+ T cells of 
miR-21–/– mice activated by anti-CD3 Ab for 3 and 6 days exhibited 
no difference in intracellular levels of GZMB (Supplemental Fig-
ure 3H) compared with WT controls. These results indicate that 
the absence of miR-21 in CD8+ T cells does not affect cell-intrinsic 
levels of GZMB and that additional mechanisms account for the 
observed differences in CD8+ TILs from miR-21–/– mice.
To test whether the increase of GZMB and CD107a in CD8+ 
TILs of miR-21–/– mice leads to more CTL activity, we isolated 
CD8+ TILs from WT or miR-21–/– tumors and immediately cultured 
them with LLCs to monitor their killing capacity. CD8+ TILs iso-
lated from miR-21–/– mice were more effective at reducing prolifer-
ation and increasing the number of apoptotic (annexin V+) target 
cells (Figure 7, J and K), indicating that miR-21 deficiency in non-
CD8+ cells within the TME improves CTL activity.
IL-12, a potent inducer of CTL activity in CD8+ T cells (37), 
was increased in TAMs of miR-21–/– mice or WT mice transplant-
ed with miR-21–/– BM (Figure 7, A and C). Thus, we hypothesized 
that increased IL-12 in miR-21–/– TAMs was responsible for the 
increased GZMB levels. Thereby, WT splenic CD8+ T cells were 
isolated and activated with an anti-CD3 Ab and incubated with 
conditioned media obtained from miR-21–/– or WT TAMs (Figure 
7L). Conditioned media from miR-21–/– TAMs led to higher levels of 
GZMB than media obtained from WT TAMs. Furthermore, a neu-
tralizing anti–IL-12 Ab blunted this effect (Figure 7L). Altogether, 
these data suggest that IL-12 from miR-21–/– TAMs participates in 
the improved T-cell responses observed in mice transferred with 
miR-21–/– BM and thus contributes to the increased tumor cell 
death observed in these animals, consistent with the enhanced 
antitumor immune response mediated by miR-21–/– TAMs.
Increased CXCL10 in miR-21–deficient TAMs mediates angiostatic 
effects within the LLC tumors. Reduced vascularization was another 
outstanding phenotype observed in tumors of mice transplanted 
with miR-21–/– BM. mir-21–/– TAMs exhibited a gene signature associ-
ated with decreased blood vessel formation. In addition to Il12, miR-
21–/– TAMs exhibited increased mRNA levels of Cxcl10 and Cxcl9. 
IL-12 in tumors negatively regulates the tumor vasculature (50). 
This effect is associated with IFN-inducible production of CXCL10 
and CXCL9, angiostatic chemokines that have been described to 
halt tumor progression by inhibiting EC proliferation and differen-
tiation into capillary structures (51). Immunofluorescent staining 
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production of IL-12 and CXCL10 in TAMs. This can explain, at least 
in part, the increased tumor cell death and reduced neovasculariza-
tion, leading to an overall reduction of tumor growth.
Conditional deletion of miR-21 in macrophages reduces tumor 
growth by promoting CTL activity and diminishing the proliferative 
phenotype of tumor-associated vasculature via increased IL-12 and 
demonstrated that CXCL10 was significantly increased in CD68+ 
TAMs from WT mice transplanted with miR-21–/– BM (Figure 8A). 
Moreover, tumor ECs (TECs) isolated from these mice showed 
reduced numbers of Ki-67+ cells compared with their control coun-
terparts (Figure 8B), indicating diminished proliferation. These 
results indicate that absence of miR-21 induces the expression and 
Figure 6. miR-21 depletion in TAMs causes a global rewiring of their transcriptional regulatory network that is skewed towards a pro-inflammatory 
phenotype and the promotion of an antitumoral immune response. Global correlation pattern between significantly upregulated genes in miR-21–/– TAMs 
and miR-21 predicted target genes. (A) Venn diagram depicting the correlation between miR-21 predicted targets (predicted ≥ 2 algorithms out of 4) vs. 
upregulated mRNAs in miR-21–/– TAMs (FC >1.5), P ≤ 0.005 Benjamini-Hochberg False Discovery Rate. The 65 genes of the miR-21–mRNA correlation study 
are depicted in the box below, including IL-12, a validated target of miR-21. (B) IPA network analysis of Regulator Effects algorithm of the 65 predicted 
targets of miR-21 significantly upregulated in miR-21–/– TAMs.
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Figure 7. miR-21 deletion in TAMs leads to improved immune response to tumors via increased IL-12. Flow cytometry analysis (A) Left: % of TAMs 
expressing IL-12 in s.c. LLC tumors of WT or miR-21–/– mice. Right: IL-12 levels (MFI) (n = 4). (B) Left: % of TAMs expressing TNF. Right: TNF levels. (C and 
D) IL-12 and TNF (as in A and B) of s.c. LLC tumors of WT mice transplanted with WT or miR-21–/– BM, (n = 6). (E) % of TAMs expressing CD40 (left) or CD86 
(right), (n = 6). (F) Left: Representative plots of GZMB in CD8+ TILs of s.c. LLC tumors of WT or miR-21–/– mice. Middle: % of CD8+ TILs expressing GZMB. 
Right: GZMB levels (n = 3). (G) % of CD8+ TILs expressing GZMB of s.c. LLC tumors of WT mice transplanted with WT or miR-21–/– BM (n = 6). (H) Left: 
Representative plots of extracellular CD107a levels in CD8+ TILs of s.c. LLC tumors of WT and miR-21–/– mice. Right: % of CD8+ TILs expressing extracellular 
CD107a (n = 3). (I) % of CD8+ TILs expressing extracellular CD107a in s.c. LLC tumors of WT mice transplanted with WT or miR-21–/– BM (n = 6). (J) Alive LLCs, 
cultured for 12 hours with CD8+ TILs from LLC tumors of WT or miR-21–/– mice at indicated effector:target ratios (n = 4). (K) % of annexin V+ LLCs, cultured 
(12 hours) with CD8+ TILs from LLC tumors of WT or miR-21–/– mice (n = 4). (L) GZMB expression by CD8+ splenocyte T cells activated with plate-bound anti–
CD3-Ab and incubated with conditioned media from cultured WT or miR-21–/– TAMs plus neutralizing anti–IL-12 or IgG Ab (n = 4). Results are mean ± SEM. 
*P < 0.05. (A–I and K) Mann-Whitney U test. (J and L) Two-way ANOVA with Bonferroni correction. (A, B, F, and H). Representative experiments out of 3 or 
(C–E, G, I, and J–L) out of 2 with similar results.
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ing on the tissue and the subpopulation of DCs analyzed (53, 54). 
Given that tumoral DCs have been described to be necessary for 
CTL activation (55, 56), we analyzed LysMCre-mediated dele-
tion of miR-21 in TAMs vs. tumor DCs. As shown in Supplemen-
tal Figure 4D, TAMs from s.c. LLC tumors of LysMCre;miR-21fl/fl 
showed efficient reduction of mR-21 levels when compared with 
TAMs isolated form control miR-21fl/fl mice. However, the expres-
sion of miR-21 in DCs isolated from LysMCre;miR-21fl/fl of miR-21fl/fl 
tumor-bearing mice was unaffected. Thus, the phenotype is not 
attributable to the deletion of miR-21 in tumor DCs.
To better understand the interaction of miR-21–deficient 
macrophages with CD8+T cells in the context of the TME, we per-
formed single-cell RNA-Seq in sorted CD45+ cells from the tumors 
of miR-21fl/fl or LysMCre;miR-21fl/fl mice. We first used unsupervised 
clustering to generate t-distributed stochastic neighbor embed-
ding (t-SNE) plots that separated the cells into distinct groups 
(Figure 11, A and B). Representation of t-SNE plots (Figure 11, 
overlay colored by sample) did not reveal overall outstanding dif-
ferences in cell populations. The same colored cells were clustered 
together in the combined sample (Figure 11B). We identified and 
classified 7 major cell types: CD8+T cells, CD4+ T cells, NK cells, 
granulocytic MDSCs, monocytic MDSCs, DCs and macrophages/
monocytes (see featured plots of selected marker gene overlays 
in Supplemental Figure 5A). Within the macrophages, 8 different 
clusters were detected. Based on gene markers of existing liter-
ature (57), proangiogenesis and proinflammatory macrophages 
were classified (Supplemental Figure 5, A and B). Within the dif-
ferent macrophage/monocyte clusters, the expression of canon-
ical differentiation markers largely overlapped (Supplemental 
Figure 5B). All remaining macrophage cluster types failed to pass 
the classification threshold for any specific macrophage type and 
stayed as “unassigned.” Because CD8+ T cells were unequivocally 
CXCL10 production. To more specifically ascertain whether the 
observed effects were a result of deletion of miR-21 in macro-
phages, we used LysMCre;miR-21fl/fl mice. LysMCre mice allow for 
both fairly specific and highly efficient (83%–98%) Cre-mediated 
deletion of mature macrophages (52).
Deletion of miR-21 in the macrophages also led to the devel-
opment of smaller tumors when compared with control mice (miR-
21fl/fl) (Figure 9, A and B). LLC tumors from LysMCre;miR-21fl/fl 
mice did not have decreased TAM infiltration; however, their MHCII 
expression was increased (Figure 9C). Tumors from LysMCre; 
miR-21fl/fl mice showed increased levels of cell death (Figure 9D), 
and although the overall number of CD8+ T cells was not affected, 
they had higher levels of GZMB and extracellular CD107a (Figure 
9E). Tumors from LysMCre;miR-21fl/fl mice also exhibited reduced 
neovascularization (Figure 9F), which was associated with reduced 
proliferating TECs (Figure 9G) and an increased percentage of 
TUNEL+ CD31+ TECs(supplemental Figure 4A). This effect could 
also be attributable to the higher levels of CXCL10 found in CD68+ 
macrophages of these tumors (Figure 9H).
To ascertain whether these effects on tumor growth were due 
to LLCs being grown in a non–organ-specific microenvironment, 
we performed orthotopic implantation of the isogenic LL/2 Red-
Fluc murine LLC-derived cell line (Figure 10, A and B) or isogenic 
B16 melanoma murine skin cancer cell line (Supplemental Figure 
4, B and C) into LysMCre;miR-21fl/fl and analyzed tumor growth. 
Deletion of miR-21 in macrophages led to the development of 
smaller tumors in these 2 different orthopic models. When cancer 
cells were implanted in an organ-specific microenvironment, the 
effect of miR-21 deficiency in macrophages was exacerbated (Fig-
ure 9, A and B, and Figure 10B).
Some reports have described LysM-mediated Cre recombina-
tion in DCs, although efficiencies range from 5% to 50% depend-
Figure 8. miR-21 deletion in TAMs leads decreased angiogenesis via 
increase of CXCL10. (A) Left: Representative images of immunoflu-
orescence costaining of CD68 and CXCL10 in frozen sections from s.c. 
LLC tumor of WT mice transplanted with WT or miR-21–/– BM cells. 
Right: Quantification of CXCL10 intensity per CD68+ cell (n = 4). (B) 
left: Representative flow cytometry plot of CD45–CD31+Ki-67+ cells 
from s.c. LLC tumors of WT mice transplanted with WT or miR-21–/–  
BM cells. Right: Average of % CD31+ Ki-67+ cells (n = 6). Results are 
mean ± SEM. *P < 0.05. Mann-Whitney U test. Representative 
experiments out of 2 with similar results. Scale bars: 70 μm.
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several granzyme coding genes, was increased in CD8+ TILs of the 
tumor immune infiltrate of LysMCre;miR-21fl/fl mice. IPA analysis 
of this set of genes showed an enrichment of gene signatures that 
promote the communication between innate and adaptive immune 
cells, as well as IL-12 signaling and Th1 immune responses (Figure 
11D). Prediction network analysis of these regulated genes showed 
IL-12 as a potential upstream regulator, while degranulation and 
cytotoxicity of T cells were predicted as downstream functions of 
these gene expression changes (Figure 11E). Importantly, block-
identified, we analyzed the changes in gene expression in CD8+ 
TILs (with intact miR-21) that were either in an immune infiltrate 
environment mostly made up of macrophages expressing miR-21 
(miR-21fl/fl) or not expressing miR-21 (LysMCre;miR-21fl/fl). Figure 
11C shows a dot plot analysis of differentially expressed genes in 
CD8+T cells of the tumor immune infiltrate of miR-21fl/fl or LysMCre; 
miR-21fl/fl mice. Interestingly, the proportion of cells with high 
expression of genes associated with an activated and cytotoxic 
phenotype, including Il12rb2, Cd69, Ifng, Ccl4, Ccl3, Cxcl10, and 
Figure 9. miR-21 expression by TAMs promotes tumor progression by inducing CD8+ T-cell suppression and angiogenesis. (A–H) Tumor analysis of  
miR-21fl/fl and LysMCre;miR-21fl/fl mice with s.c. injection of LLCs (n = 7). LLC tumor volume (A), final tumor weight (B). (C) Left: Average % of TAMs of s.c. 
LLC tumors. Right: MHC II surface levels in TAMs (average MFI) (n = 6 out 7 randomly selected). (D) Left: Representative images of TUNEL and DAPI stain-
ing of cross sections of s.c. LLC tumors. Right: Quantification of % DAPI+ TUNEL+ cells (n = 7). (E) Flow cytometry analysis of CD8+ TILs in s.c. LLC tumors. 
Average % of CD8+ TILs (left), % of CD8+ TILs expressing GZMB (middle) and % of CD8+ TILs with extracellular CD107a (right) (n = 7). (F) Representative 
images of CD31 staining of cross sections of s.c. LLC tumors. Right: Quantification of CD31+ vessel-like structures (n = 7). (G) Average % CD31+ Ki-67+ cells 
of s.c. LLC tumors (n = 7). (H) Left: Representative images of immunofluorescence costaining of CD68 and CXCL10 in frozen sections of s.c. LLC tumors. 
Right: Average quantification of CXCL10 intensity per CD68+ cell (n = 3, out of 7 randomly selected). Results are mean ± SEM. *P < 0.05. (A) Two-way 
ANOVA (time and genotype) with Bonferroni correction, #P < 0.05 individual comparisons. (B–H) Mann-Whitney U test. (A–H) Representative experiment 
out of 2 with similar results. Scale bars: 70 μm.
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and C). Interestingly, splenic macrophages did not show any pHLIP 
Var3-AF546 cell incorporation. When compared with other cells of 
the tumor immune infiltrate, also in an acidic microenvironment, 
TAMs seem to be more efficient at incorporating pHLIP Var3-
AF546 because a greater number of cells showed a higher amount 
of inserted peptide when compared with CD4+ or CD8+ T cells and 
DCs (Supplemental Figure 6F). Interestingly, nonimmune cells of 
the TME, including ECs did not efficiently internalize pHLIP when 
compared with CD68+ macrophages within the tumor (Supple-
mental Figure 6F). These data indicate that pHLIP is an efficient 
way to target not only cancer cells but also TAMs.
We then assessed the therapeutic antitumor efficacy of pHLIP 
anti–miR-21 PNA in vivo. The PNAs were also tagged with TAMRA 
for visualization. Intravenous administration of pHLIP anti–miR-21 
to mice with orthotopic and heterotopic lung cancer tumors result-
ed in a significant reduction in tumor growth when compared with 
mice injected with pHLIP anti–miR-mismatch control (Supple-
mental Figure 8, A and B, and Figure 13A). Furthermore, enhanced 
delivery (TAMRA fluorescence) to macrophages within the tumor 
was detected by flow cytometry and by immunofluorescence in 
CD68+ macrophages (Supplemental Figure 6, D and E, respective-
ly). Despite the fact that DCs also became glycolytic upon activa-
tion (64), we only found a small proportion of DCs that showed low 
levels of incorporation of pHLIP Var3-AF546 (Supplemental Figure 
6, A–C) or pHLIP anti–miR-21-TAMRA (Supplemental Figure 6, D 
and E). This was not sufficient to reduce miR-21 levels in DCs or 
affect miR-21 target expression (Supplemental Figure 6G).
To avoid targeting cancer cells expressing miR-21, we used 
CRISPR/Cas9-mediated genome editing to KO miR-21 from 
LLC cells (miR-21–/– LLCs) (Supplemental Figure 7). The effect of 
pHLIP anti–miR-21 was assessed in mice bearing miR-21–/– LLC 
tumors (Figure 13B). pHLIP anti–miR-21 administration still 
reduced tumor burden in mice bearing miR-21–/– LLC tumors, sug-
gesting that targeting miR-21 in TAMs is sufficient to efficiently 
diminish tumor growth. Moreover, increased tumor cell death 
and reduced neovascularization were also observed (Figure 13, C 
and D). mRNA levels of miR-21 targets such as Il12, Tnf, or Cxcl10 
were increased in sorted TAMs from miR-21–/– LLC tumors that 
were administered pHLIP anti–miR-21 (Figure 13E), indicating 
efficient miR-21 inhibition in TAMs. We also observed improved 
T-cell responses as indicated by increased GZMB and degranula-
ade of IL-12 and CXCL10 in tumor-bearing LysMCre;miR-21fl/fl 
mice produced an increase in tumor growth as compared with 
LysMCre;miR-21fl/fl mice treated with an isotype control (Figure 12, 
A and B). Furthermore, we observed a reduction in the expression 
of GZMB in CD8+ TILs when IL-12 and CXCL10 were neutralized 
in LysMCre;miR-21fl/fl mice (Figure 12C), as well as an increase in 
neovascularization (Figure 12D). On the whole, our results pro-
vide evidence that the decreased tumor growth, improved CTL 
response, and decreased neovascularization observed in animals 
lacking miR-21 in TAMs is mediated, at least in part, by increased 
IL-12 and CXCL10.
Antagonism of miR-21 in macrophages reduces tumor progression 
even when miR-21 is not expressed in cancer cells. Given the desirable 
outcomes that miR-21 deficiency in macrophages produces, we 
aimed to specifically inhibit miR-21 in macrophages during tumor 
progression. We took advantage of a pHLIP, which is a carrier pep-
tide that under acidic conditions can insert directionally across cell 
membranes and thereby translocate otherwise membrane-imper-
meable cargo molecules into cells via a nonendocytic route (58). 
Given the acidic conditions found in solid tumors, pHLIP has been 
shown to home to a variety of tumors when administered system-
ically (59). pHLIP has been coupled to antisense nucleic acid ana-
logues consisting of peptide nucleic acids (PNAs), to create deliv-
ery vectors to successfully silence tumor miRNAs (60). The acidic 
environment found in the tumor has been largely attributed to the 
high glycolytic rate of tumor cells (61). TAMs have also activated 
aerobic glycolysis and thus contribute to a local acidification within 
the TME (62). We wondered whether pHLIP would also efficiently 
accumulate in TAMs in addition to tumor cells. Enhanced insertion 
of pHLIP into a variety of cells has been shown under acidic condi-
tions in vitro (58). However, internalization of pHLIP by different 
cell types within the tumor has not been reported. Thus, we s.c. 
implanted eGFP-LLCs, and 2 weeks, later mice were injected with 
pHLIP Variant 3 (Var3) conjugated with fluorescent Alexa546 (63). 
Single cells of the tumor were isolated, and Alexa546 fluorescence 
was analyzed via flow cytometry. We found that in addition to can-
cer cells (eGFP LLCs), the fluorescent signal from pHLIP Var3-
AF546 was also detected in TAMs (Supplemental Figure 6, A–C). 
Although the percentage of cancer cells that incorporated pHLIP 
Var3-AF546 was higher (Supplemental Figure 6A), the cell-associ-
ated fluorescence was greater in TAMs (Supplemental Figure 6, B 
Figure 10. miR-21 expression by TAMs promotes tumor progression in lung tumors. (A and B) Bioluminescence imaging and final tumor weight of lung 
tumors generated by LL/2Red Luc injected orthotopically into the lungs of miR-21fl/fl and LysMCre;miR-21fl/fl mice. For tumor weight in B, remaining healthy 
lung tissue was removed. (n = 5 and 6, respectively). Results are mean ± SEM. *P < 0.05. (A) Two-way ANOVA (time and genotype) with Bonferroni correc-
tion, #P < 0.05 individual comparisons. (B) Mann-Whitney U test. Representative experiment out of 2 with similar results. Scale bars: 70 μm.
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Figure 11. Increased cytotoxic program and phenotype in CD8+ TILs is the result of miR-21 deletion in macrophages. (A) Overlaid t-SNE plots colored by 
sample of CD45+ cells isolated from s.c. LLC tumors of miR-21fl/fl and LysMCre;miR-21fl/fl mice. (B) Recolored t-SNE plot based on matching results for the 
combined dataset distinct groups of cells separated and manifested. See feature plots of select marker gene overlays in Supplemental Figure 2A. (C) Dot 
plot analysis of differentially expressed genes in CD8+T cells of s.c. LLC tumor immune infiltrate of LysMCre;miR-21fl/fl or LysMCre;miR-21fl/fl mice. (D) IPA 
analysis of set of genes differentially regulated in CD8+ T cells from s.c. LLC tumors of LysMCre;miR-21fl/fl versus miR-21fl/fl mice. Dot size represents the 
fraction of cells expressing the gene, and red color represents a greater than 1.5-fold gene expression among expressing cells. (E) IPA network analysis 
using Regulator Effects algorithm of gene set differentially regulated in CD8+ T cells from LLC tumors of LysMCre;miR-21fl/fl versus miR-21fl/fl mice.
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I NSLC show that high expression of miR-21 in the nontumor cells 
of the TME is significantly associated with reduced overall surviv-
al. In agreement with these findings, a recent report shows that 
increased expression of miR-21 in the TME, but not in cancer cells, 
was associated with a poor prognosis for patients with lung adeno-
carcinoma (31). This effect was linked with increased expression 
of miR-21 in cancer-associated fibroblasts (CAFs) (31), similar to 
what has been reported in pancreatic and colorectal tumors (21–
23). However, the underlying mechanisms of cancer-associated 
fibroblast–miR-21 promoting tumor growth were only investigat-
ed in vitro. We show that the expression of miR-21 in infiltrated 
immune cells, not stromal cells, is responsible for promoting 
tumor growth. This finding was supported by the decreased tumor 
growth in WT mice adoptively transferred with miR-21–/– BM, 
whereas reverse BMT (WT BM to miR-21–/– recipients) produced a 
converse effect. This observation was in agreement with a recent 
study that also used BM adoptive transplant to show that deletion 
of miR-21 in immune cells reduces tumor growth (25). Elevation of 
miR-21 levels has been observed in MDSCs directly derived from 
BM cells that were stimulated with GM-CSF and IL-6, as well as 
MDSCs from tumor-bearing mice (19), and in vitro overexpres-
sion or inhibition of miR-21 in BM cells altered MDSC expansion 
(19). However, within the tumor infiltrate of miR-21–/– or WT mice 
adoptively transferred with miR-21–/– BM, we did not find differ-
ences in the proportion of monocytic or granulocytic MDSCs 
when compared with controls. This finding indicates that the in 
vivo absence of miR-21 in MDSCs does not have a major effect on 
this population. Similarly, when we analyzed TILs, we did not find 
differences in the percentage of IFNG expressing CD4+ or CD8+ 
tion in CD8+ TILs (Figure 13F). Furthermore, increased levels of 
CXCL10 in CD68+ macrophages of these tumors was associated 
with reduced CD31+ capillary structures (Figure 13G).
Taken together, these results show that targeting miR-21 in 
macrophages promotes an antitumoral immune response and an 
overall proinflammatory angiostatic function that results in a sig-
nificant reduction in tumor growth.
Discussion
In this study, we have used a variety of different mouse models to 
assess how miR-21 in noncancerous cells of the TME contributes 
to tumor progression. Cancer initiation and progression has been 
historically defined by the behavior of cancer cells, including reg-
ulation by miRNAs, which have an impact on many of the autono-
mous functions of cancer cells to either promote or suppress tumor 
growth (1). Importantly, miRNAs in cells from the TME have also 
emerged as key players involved in the development and progres-
sion of cancer (5–7, 65).
Our results using syngeneic heterotopic and orthotopic lung 
cancer models demonstrate that miR-21 expression in noncancer-
ous cells plays an important role in tumor progression, in agree-
ment with reports using other models (24, 25). However, the exist-
ing literature fails to fully elucidate the cell compartment of the 
TME in which miR-21 primarily contributes to tumor progression, 
often relying on in vitro systems or approaches that globally target 
miR-21 in a non–cell/tissue-specific manner (19–25, 31).
Within the TME, miR-21 has been reported to be increased in 
many types of cancer (22, 27, 31, 66), and this increase was linked 
to tumor progression. Our data, in 3 cohorts of patients with stage 
Figure 12. Neutralization of IL-12 and CXCL10 decreases tumor growth, improved CTL response, and decreased neovascularization in animals lacking miR-
21 in macrophages. Tumor analysis of miR-21fl/fl and LysMCre;miR-21fl/fl mice with s.c. injection of LLCs (n = 6) and treated with 200 μg of anti–IL-12 + 100 μg 
of anti-CXCL10 neutralizing antibodies or 300 μg of isotype control on the indicated days. LLC tumor volume (A), final tumor weight (B). (C) Flow cytometry 
analysis of CD8+ TILs. Left: Average % of CD8+ TILs expressing GZMB, Right: GZMB levels (average MFI) (n = 6). (D) Representative images of CD31 immu-
nostaining of cross sections. Right: Quantification of CD31+ vessel-like structures (n = 6). Results are mean ± SEM. *P < 0.05. (A) Two-way ANOVA (time and 
genotype) with Bonferroni correction. (B–D) Kruskal-Wallis test. (A–D) Representative experiment out of 2 with similar results. Scale bars: 70 μm.
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Figure 13. Targeting macrophage miR-21 leads to improved T-cell responses and decreased angiogenesis. (A) Tumor progression in WT mice injected 
s.c. with 106 LLCs in the dorsal flank and treated with 1 mg/kg pHLIP anti–miR-21 or pHLIP anti–miR-21-mismatch control on indicated days (n = 6). (B) 
Tumor progression in WT mice injected s.c. with 106 with miR-21–/– LLC and treated with 1 mg/kg pHLIP anti–miR-21 or pHLIP anti–miR-21-mistmatch on 
indicated days (n = 6). (C) Representative images of TUNEL and DAPI staining of cross sections of miR-21–/– LLC tumors of WT mice treated as in B. Right: 
Quantification of % DAPI+ TUNEL+ cells (n = 4 out of 6 randomly selected). (D) Representative images of CD31 staining of cross sections of miR-21–/– LLC 
tumors of WT mice treated as in B. Right: Quantification of CD31+ vessel-like structures (n = 4 out of 6 randomly selected). (E) qRT-PCR analysis of relative 
mRNA levels of validated or predicted targets of miR-21 (Il12, Tnf, and Cxcl10) in sorted TAMs (CD45+ CD11b+ MHC II+ F4/80+) of miR-21–/– LLC tumors of WT 
mice treated as in B (n = 3 out of 6 randomly selected). (F) Right: Flow cytometry analysis of average % of CD8+ TILs expressing GZMB. Left: % CD8+ TILs 
with extracellular CD107a in miR-21–/– LLC tumors of WT mice treated as in B (n = 4 out 6 randomly selected). (G) Left: Representative images of immu-
nofluorescence costaining of CD68 and CXCL10 in frozen sections of miR-21–/– LLC tumors of WT mice treated as in B. Right: Average of quantification of 
CXCL10 intensity per CD68+ cell (n = 4 out 6 randomly selected). Results are mean ± SEM. *P < 0.05. (A and B) Two-way ANOVA (time and genotype) with 
Bonferroni correction, #P < 0.05 individual comparisons. (C–G) Mann-Whitney U test. Scale bars: 70 μm.
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LysMCre;miR-21fl/fl also showed increased levels of cell death and 
their CD8+ T cells (expressing miR-21). They also had higher levels 
of GZMB and extracellular CD107a, suggesting that the absence 
of miR-21 in TAMs can influence other cells within the TME.
Our present results indicate that the observed changes in the 
levels of chemokines and cytokines in miR-21–deficient TAMs 
are critical for CTL activation and antitumor activity. Specifical-
ly, we found that increased IL-12 in miR-21–/– TAMs is responsible 
for the increased GZMB levels independent of miR-21 expression 
in CD8+ T cells. This finding was supported by our single-cell 
RNA-Seq analysis, where we analyzed the changes in gene expres-
sion in CD8+ TILs from tumors in which TAMs lacked miR-21. In 
LLC tumors from LysMCre;miR-21fl/fl mice, the CD8+ TILs exhibit 
increased expression of genes associated with an activated and 
cytotoxic phenotype, including Il12rb2, Cd69, Ifng, Ccl4, Ccl3, 
Cxcl10, and several granzyme coding genes. These results provide 
evidence that the improved CTL response is the result of miR-21 
deletion in macrophages.
In addition to the effects on T-cell functions, the increased 
levels of IL-12 in LysMCre;miR-21fl/fl mice could also play an 
important role in regulation of tumor angiogenesis, as IL-12 has 
been shown to negatively regulate tumor neovascularization (50). 
This effect has been associated with IFN-inducible production of 
CXCL10 and CXCL9 (51). Macrophages lacking miR-21 exhibited 
an increased production of CXCL10, which binds to the CXCR3-B 
receptor on endothelial cells, resulting in suppression of endothe-
lial cell proliferation and differentiation into capillary structures 
(51). CXCL10 selectively attracts Th1 cells and functions as a pos-
itive feedback loop in the Th1-driven antitumor immune response 
(45). The tumors from LysMCre;miR-21fl/fl mice exhibited reduced 
neovascularization, a reduced number of proliferating TECs, and 
an increased percentage of TUNEL+ CD31+ TECs. Taken together, 
our present work indicates that the absence of miR-21 in macro-
phages favors the formation of a tumor- suppressive microenvi-
ronment (45), characterized by increased expression of IL-12 and 
CXCL10 that leads to improved CTL response, decreased neovas-
cularization, and decreased tumor burden.
Macrophages are perhaps the most important immune cells 
that infiltrate the tumor and affect its pathology (71, 72). Although 
macrophages can show some antitumor activity (73), they mostly 
promote a net protumor outcome because they have been shown 
to be capable of dampening T-cell responses and stimulating 
angiogenesis, among others actions (47, 74). This phenomenon, 
which has been widely accepted, is promoted by tumor cells that 
create a widespread tolerogenic environment through the release 
of tumor-derived factors that promote the expansion and repro-
gramming of TAMs to block T-cell functions and promote several 
protumor events. TAMs are recognized as an important target for 
therapeutic intervention (75). Our data highlight the central role of 
miR-21 in regulation of TAM activity and function regarding CTL 
regulation and neovascularization. Thus, to determine whether 
the high expression of miR-21 in TAMs may make it a likely target 
for therapeutic intervention, we opted to use pHLIP anti–miR-21 
PNA. pHLIP carriers coupled to antisense nucleic acid analogues 
are delivery vectors that have been shown to successfully target 
miRNAs in tumor cells (60, 76). Here, we show for the first time 
that TAMs incorporate pHLIP as efficiently as tumors cell and 
T cells, in agreement with a recent report (25). In other settings, 
miR-21 has been shown to regulate cell-autonomous T-cell func-
tion (67, 68). In the context of tumor progression, a report showed 
that absence of miR-21 reduced the proliferation of both CD4+ and 
CD8+ cells and their cytokine production, thus accelerating the 
growth of grafted tumors (24). In this case, growth of an implant-
ed S180 mouse cancer cell line was analyzed in miR-21 floxed 
expressing the global Cre driver. S180 cells have been shown to 
grow in multiple inbred mouse strains due to β2-microglobulin 
deficiency, MHC class I destabilization, and impaired recognition 
by host CTLs (69). In this setting and without using a syngeneic 
mouse model and/or conditional deletion of miR-21 in T cells, it 
was concluded that miR-21 expression in T cells was protective 
against tumor growth (24).
Several studies have described correlations between mac-
rophage number, location, and phenotypic characteristics and 
clinical outcomes (70). In our human TMAs, we found that high 
expression of miR-21 in CD68+ macrophages within the TME 
compartment had a negative impact in patient disease-specific 
survival and shows the relevance of miR-21 in macrophages for 
tumor progression. In line with miR-21 being the most abun-
dant miRNA in macrophages (10), we found that within the LLC 
tumors, miR-21 is highly expressed in TAMs compared with the 
rest of the tumor immune infiltrate. Because conflicting results 
have been reported regarding the role of miR-21 in regulating the 
inflammatory responses of macrophages (10, 13–15, 17, 18, 43), we 
specifically focused on how miR-21 regulates the gene expression 
and functions of TAMs. miR-21 deficiency in TAMs produced a 
global rewiring of their transcriptional regulatory network that is 
skewed toward a proinflammatory phenotype and the promotion 
of an antitumoral immune response. Importantly, we show that 
selective deletion of miR-21 in macrophages in a heterotopic and 
orthotopic model of lung cancer mimicked the effects of global 
or hematopoietic loss of miR-21, with smaller tumors, increased 
cell death, and reduced neovascularization. Moreover, we found 
increased GZMB and degranulation of CD8+ TILs, indicating 
increased CTL activity and heightened killing capacity, con-
sistent with the higher levels of cell death within the tumors of 
LysMCre;miR-21fl/fl mice. These findings support the report of Baer 
and colleagues who showed that disruption of miRNA processing 
in TAMs, by LysM-Cre–mediated deletion of Dicer1, leads to the 
development of smaller LLC tumors and improved CTL activity 
(5). This study highlights how the loss of mature miRNAs in TAMs 
during tumor progression leads to increased classically activated 
TAMs, improved CD8 response, and decreased CD8 suppression, 
which was associated with higher expression of CXCL10, CD86, 
and CXCL9 in the tumors (5). In fact, because miR-21 is highly 
expressed in macrophages (10), many of these changes could be 
attributed to the loss of expression of miR-21 after Dicer1 deletion.
A recent report using a B16 tumor model suggested that mice 
receiving miR-21–deficient BM had higher numbers of “M1” 
TAMs with tumoricidal polarization, whereas miR-21 deficiency in 
T cells reduced their ability to produce proinflammatory cytokines 
and cytolytic granules (25). On the contrary, our data indicate that 
CD8+ TILs from miR-21–/– mice have increased GZMB expression 
and killing capacity. However, the increased GZMB expression is 
not due to miR-21 deletion in these cells because LLC tumors from 
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roni correction for multiple comparisons. Normality was checked using 
the Kolmogorov–Smirnov test. A nonparametric test, Mann-Whitney 
U, test or a Kruskal-Wallis test for multiple comparisons, was used 
when data did not pass the normality test. For RNA-Seq analysis, we 
used Benjamini-Hochberg False Discovery Rate. Survival curves were 
generated by Kaplan–Meier analysis and tested for significance using 
the Mantel-Cox log-rank test. A value of P ≤ 0.05 was considered sta-
tistically significant. Data analysis was performed using GraphPad 
Prism Software Version 7.
Study approval. Animal experiments were conducted under the 
ethical guidelines and protocols approved by IACUC at Yale Universi-
ty School of Medicine (Animal protocol no. 2019-116576). All human 
tissues were collected with the approval from the Yale Human Inves-
tigation Committee (protocol no. 9505008219). The Yale Human 
Investigation Committee approved the patient consent forms or in 
some cases, a waiver of consent.
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strikingly more effectively than other cells of the TME. pHLIP 
anti–miR-21 administration in WT mice reduced tumor burden 
even under conditions where tumor cells lacked miR-21 expres-
sion. Importantly, CD8+ TILs showed increased GZMB expres-
sion and tumors had reduced neovascularization. Sorted TAMs 
of pHLIP anti–miR-21 treated mice exhibited increased IL-12 
and CXCL10 expression, similar to TAMs of LysMCre;miR-21fl/fl 
mice. Thus, targeted inhibition of miR-21 in TAMs is sufficient to 
increase CTL activity and decrease angiogenesis, thereby dimin-
ishing tumor growth.
Numerous studies have shown that within cancer cells, miR-21 
acts as an oncomiR, and anti–miR-21 therapy (RG-012) is already 
in the pipeline for clinical trials. Our findings demonstrate the criti-
cal role of miR-21 within TAMs for promoting tumor development, 
indicating that targeting of miR-21 may have the added benefit of 
improving CTL activity and limiting tumor angiogenesis through 
its effects on TAMs. Our findings in human patients with NSCLC 
suggest this may have a critical impact on patient outcomes. Final-
ly, our results indicate that use of pHLIP targeted therapies allows 
for effective targeting of both tumor cells and TAMs, while avoid-
ing possible unintended effects on other tissues and organs.
Methods
Detailed information on experimental procedures and reagents is 
provided in Supplemental Tables 1–3, Supplemental Figure 7, and 
Supplemental Methods.
Mice. Experiments were conducted under the ethical guide-
lines and protocols approved by IACUC (Institutional Animal Care 
and Usage Committee) in Yale University School of Medicine. WT 
C57BL/6 or miR-21–/– (Mir21atm1Yoli/J, Jax no. 016856) mice were 
purchased from The Jackson Laboratory. miR-21–/– mice were bred 
with C57BL/6 mice for several generations in order to ensure they 
were syngeneic and on C57BL/6 background. LysMCre;miR-21fl/fl on 
C57BL/6 background mice were generated by breeding miR-21fl/fl 
(Mir21tm1Mtm/Mmjax, Jax no. 36060) on C57BL/6 background with 
LysMCre (Lyz2tm1(cre)Ifo, Jax no. 004781); miR-21fl/fl in C57BL/6 back-
ground were used as control counterparts.
Data and software availability. All RNA-Seq and single-cell RNA-
Seq data were deposited in the NCBI’s Gene Expression Omnibus 
database (GSE117697 and GSE118931).
Statistics. Data are presented as mean ± SEM. Statistical differenc-
es were measured using 1-way ANOVA or 2-way ANOVA with Bonfer-
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